Epigenetic therapy with histone deacetylase inhibitors (e.g., valproic acid) and DNA demethylating agents is being evaluated in AD or PD, which exploits the reactivation of Nrf2 expression and enzyme activity. This evidence concerns the gene NFE2L2 and Parkinson disease.